Lymphoma  >>  Gazyva (obinutuzumab) 
Welcome,         Profile    Billing    Logout  

107 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
GAZELLE, NCT03817853: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed
4
114
Europe, Japan, US, RoW
Obinutuzumab, GA101, RO5072759, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Hoffmann-La Roche
Advanced Follicular Lymphoma
08/20
01/23
2018-003255-38: A Study of Gazyva Short Duration Infusion (SDI) in Patients with Previously Untreated Follicular Lymphoma

Not yet recruiting
4
112
Europe
Obinutuzumab, RO5072759, Concentrate for solution for infusion, Gazyvaro
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Follicular lymphoma, Follicular lymphoma (FL) is one of the most common common B cell-indolent non-Hodgkin's lymphomas (NHL) [type of blood cell cancer of the immune system], Diseases [C] - Cancer [C04]
 
 
CLL14 study, NCT02242942 / 2014-001810-24: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Checkmark 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Dec 2020 - Dec 2020: 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Checkmark From CLL-14 trial in combination with Gazyva in CLL
Sep 2020 - Sep 2020: From CLL-14 trial in combination with Gazyva in CLL
Checkmark From CLL-14 trial in combination with Gazyva in CLL at ASCO 2020
More
Active, not recruiting
3
445
Europe, Canada, US, RoW
Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva
Hoffmann-La Roche, AbbVie, German CLL Study Group
Lymphocytic Leukemia, Chronic
08/18
08/25
ELEVATE-TN, NCT02475681 / 2014-005582-73: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Hourglass Dec 2023 - Dec 2023 : Data from ELEVATE-TN in treatment-naive chronic lymphocytic leukemia at ASH 2023
Checkmark Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Checkmark 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
More
Active, not recruiting
3
535
Europe, Canada, US, RoW
Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN
Acerta Pharma BV
Chronic Lymphocytic Leukemia
02/19
09/25
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
NCT02035462 / 2009-012476-28: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
3
787
US, Canada, Europe, RoW
RO5072759, rituximab, chlorambucil
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., , F.Hoffmann-La Roche Ltd.
Lymphocytic Leukemia, Chronic
06/21
06/21
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko

Not yet recruiting
3
178
Europe
Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto
German CLL Study Group (University of Cologne), AstraZeneca
Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04]
 
 
NCT03406156: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed
3
120
US
Obinutuzumab, Gazyva, Bendamustine, Bendeka, Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/21
07/23
2021-000362-15: Therapy of follicular lymphoma with radiotherapy an antibody

Not yet recruiting
3
130
Europe
Concentrate for solution for infusion, GAZYVARO, MabThera
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial, Roche Pharma AG, Department of Radiation Oncology, Universityhospital Heidelberg
nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification), nodal follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1080
Europe, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
05/37
05/37
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
CRISTALLO, NCT04285567: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Active, not recruiting
3
166
Europe, US, RoW
Obinutuzumab, Gazyva, RO5072759, GA101, Venetoclax, Venclexta, RO5537382, GDC-0199, Fludarabine, Cyclophosphamide, Rituximab, MabThera, Rituxan, Bendamustine, Treanda, Levact, Ribomustin
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
03/24
07/26
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting
3
120
NA
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
10/26
10/26
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL
Recruiting
3
270
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
04/25
04/25
GLOBRYTE, NCT06084936: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
3
182
Europe, Canada, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab
Hoffmann-La Roche
Lymphoma
02/26
12/26
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
NCT05211856: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Recruiting
3
780
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
ACE-CL-311, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Calendar Jan 2027 - Mar 2027: Last patient dosing of P3 ACE-CL-311 trial in combination with venetoclax for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Data from AMPLIFY trial in combination with Calquence and obinutuzumab for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with venclexta and obinutuzumab for 1L CLL (based on AMPLIFY trial)
Hourglass Jul 2022 - Dec 2022 : From P3 ACE-CL-311 trial in combination with Venclexta for 1L CLL
Active, not recruiting
3
984
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
Acerta Pharma BV, AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
MAJIC, NCT05057494 / 2021-003936-10: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
3
607
Europe, US, RoW
Acalabrutinib, Venetoclax, Obinutuzumab
AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
07/27
04/29
MAHOGANY, NCT05100862: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting
3
750
Europe, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Rituximab, Rituxan, MabThera, Ruxience, Truxima, Lenalidomide, Revlimid, Obinutuzumab
BeiGene
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
07/28
06/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-001033-27: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW) REMODEL - WM3 Etude ouverte de phase II évaluant l’efficacité d’un traitement «sans chimiothérapie » par l’association de l’Idelalisib avec l’Obinutuzumab chez les patients atteints de la Maladie de Waldenström (MW)

Ongoing
2
50
Europe
Obinutuzumab, R05072759/F06-01, Concentrate for solution for infusion, Film-coated tablet, Gazyvaro, Zydelig
FILO, Roche, GILEAD
Waldenstrom’s Macroglobulinemia (MW) Macroglobulinémie de Waldenstrom (MW), Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia Patient en rechute ou réfractaire d'une macroglobulinémie de Waldenstrom, Diseases [C] - Cancer [C04]
 
 
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens

Ongoing
2
70
Europe
obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro
HOVON Foundation, Dutch Cancer Society, Roche
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
OBI-1, NCT03679455 / 2016-005053-20: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia,

Recruiting
2
30
Europe
Obinutuzumab 25 MG/ML, Gazyvaro
Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A.
Waldenstrom Macroglobulinemia
04/19
12/22
2018-001229-18: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazione con Obinutuzumab (G) per il trattamento di pazienti con linfoma follicolare ricaduto/refrattario: studio multicentrico di fase II a braccio singolo.

Not yet recruiting
2
43
Europe
Zydelig, GAZYVARO, [IMP1], [Obinutuzumab], Capsule, hard, Concentrate for solution for infusion, Zydelig, Gazyvaro
FONDAZIONE ITALIANA LINFOMI ONLUS, GILEAD, ROCHE
recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
2018-004038-13: Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burden

Not yet recruiting
2
102
Europe
Copanlisib, Obinutuzumab, BAY 80-6946, RO5072759/F06-01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Gazyvaro
Klinikum der Universität München, Bayer HealthCare Pharmaceuticals Inc., Roche Pharma AG
Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated), Follicular Lymphoma with need of treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
GAZAI, NCT03341520 / 2016-002059-89: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Active, not recruiting
2
89
Europe
Obinutuzumab Injection [Gazyva], Gazyvaro, Low dose radiation Therapy (LDRT)
Heidelberg University, Roche Pharma AG
Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2
11/21
05/24
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
ROSEWOOD, NCT03332017 / 2017-001552-54: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Active, not recruiting
2
217
Europe, Canada, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Obinutuzumab, Gazyva
BeiGene
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
10/21
10/24
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio.

Not yet recruiting
2
78
Europe
Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
17P.176, NCT03198026: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Recruiting
2
30
US
Ibrutinib, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, 936563-96-1, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, Gazyva, R7159, RO 5072759, GA-101, GA101, huMAB(CD20), RO-5072759, RO5072759, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc., Pharmacyclics LLC.
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
12/24
02/31
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Terminated
2
32
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services
Central Nervous System B-Cell Non-Hodgkin Lymphoma
03/24
03/24
NCT04883437: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting
2
49
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, AstraZeneca, National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
01/24
01/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Venetoclax and Obinutuzumab for 1L CLL at ASH 2022
Active, not recruiting
2
72
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
04/24
12/27
NCT06333262: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab
Inhye Ahn, Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/27
02/29
NCI-2024-00209, NCT06213311: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, RG6026, Obinutuzumab, GA101, Gazyva, RO5072759, Axi-cel, Axicabtagene ciloleucel, KTE-C19, KTE-X19
M.D. Anderson Cancer Center, Genentech, Inc., Kite, A Gilead Company
B Cell Lymphoma
01/25
01/27
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCI-2024-00054, NCT06252675: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
50
US
Obinutuzumab, Anti-CD20 Monoclonal Antibody R715, huMAB(CD20), RO5072759, Glofitamab, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO7082859, Pirtobrutinib, LOXO-305, Tumor Imaging, FDG-PET, Computed Tomography (CT), Biospecimen Collection, Biological Sample Collection, ClonoSeq Assay, ClonoSeq, Bone Marrow Biopsy, Biopsy of Bone Marrow
C. Babis Andreadis, Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Mantle Cell Lymphoma
07/28
07/28
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
12/25
12/25
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
ReVenG, NCT04895436 / 2021-001037-39: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting
2
75
Europe, US, RoW
Venetoclax, Venclexta, ABT-199, GDC-0199, Obinutuzumab, GA101, Gazyva
AbbVie, F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
02/25
01/29
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
NCT06108232: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting
2
36
US
Obinutuzumab, GA101, Gazyva, RO5072759, CC-99282
M.D. Anderson Cancer Center, Bristol-Myers Squibb
Follicular Lymphoma, Tumor
12/25
12/27
NCT05783596: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Recruiting
2
50
US
Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Glofitamab, RO7082859
Reid Merryman, MD, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
01/26
01/29
NCT04447768: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
100
US
Obinutuzumab, Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Chronic Lymphocytic Leukemia (CLL)
07/26
07/26
BruVenG, NCT05650723: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Recruiting
2
50
US
Zanubrutinib Pill, Brukinsa, Venetoclax Pill, Venclexta, Obinutuzumab Injection, Gazyva
Weill Medical College of Cornell University, BeiGene, Genentech, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
01/25
12/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Not yet recruiting
2
99
NA
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
01/27
07/28
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
OAsIs, NCT02558816 / 2014-003740-13: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Active, not recruiting
1/2
48
Europe
Ibrutinib + GA101 +GDC-0199, GA101 : Obinutuzumab, Ibrutinib, GDC-0199
Nantes University Hospital, Janssen, LP, Roche Pharma AG
Mantle Cell Lymphoma
04/19
10/25
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
NCT02315768: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Active, not recruiting
1/2
32
US
GA101, Obinutuzumab, ibrutinib
University of California, San Diego, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/23
11/23
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT06357676: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Not yet recruiting
1/2
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Oregon Health and Science University, Genentech, Inc.
Mantle Cell Lymphoma
05/27
05/29
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
NCT04855695: Avo In R/R And Previously Untreated MCL

Recruiting
1/2
53
US
Acalabrutinib, Calquence, Acalabrutinib maleate, Venetoclax, Venclexta, Obinutuzumab, Gazyva
Austin I Kim, AstraZeneca, Genentech, Inc.
Mantle Cell Lymphoma, Refractory Lymphoma
12/24
06/26
NP30179, NCT03075696: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Checkmark Data from P2 portion of P1/2 trial for DLBCL
Dec 2022 - Dec 2022: Data from P2 portion of P1/2 trial for DLBCL
Checkmark Data from trial for 3L+ LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from trial for 3L+ LBCL at ASH 2022
Checkmark Safety and efficacy of phase 1/2 study for mantle cell lymphoma at ASH 2022
More
Recruiting
1/2
860
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, Gazyva®, Gazyvaro™, Tocilizumab, Actemra®, Roactemra®
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
08/25
08/25
NCT02229422: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)

Active, not recruiting
1/2
40
US
GA101/HDMP
University of California, San Diego, Genentech, Inc.
CLL
10/25
12/25
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
C4971006, NCT05896163: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Recruiting
1/2
70
Japan, US, RoW
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
Pfizer, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
06/26
06/28
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27
NCT02417285: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Checkmark For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Checkmark In R/R DLBCL or iNHL at ASH 2016
Dec 2016 - Dec 2016: In R/R DLBCL or iNHL at ASH 2016
Completed
1b
75
Europe
Obinutuzumab, GA-101, CC-122
Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
05/19
09/23
NCT04434196: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, not recruiting
1b
50
Europe, Canada, US
CC-99282, Obinutuzumab
Celgene
Lymphoma, Non-Hodgkin
11/24
05/25
jRCT2080225077: A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Completed
1
12
Japan
Columvi (glofitamab) - Roche, Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Actemra IV (tocilizumab) - Roche, JW Pharma
Chugai Pharmaceutical Co., Ltd.
 
 
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
1
54
US
Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Genentech, Inc.
Chronic Lymphocytic Leukemia
03/20
01/29
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Active, not recruiting
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
09/27
YO42610, NCT04657302: A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed
1
30
RoW
Obinutuzumab, Glofitamab, Tocilizumab
Hoffmann-La Roche
Lymphoma
10/22
01/24
NCT04245722: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated
1
98
US
FT596, Cyclophosphamide, Fludarabine, Rituximab, Rituxan, Truxima, Ruxience, Obinutuzumab, Gazyva, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
09/23
09/23
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
ISRCTN17975931: A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma

Recruiting
1
36
Australia, Belgium, Denmark, Italy, Poland, Spain, US
Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Columvi (glofitamab) - Roche, dexamethasone - Generic mfg., Actemra IV (tocilizumab) - Roche, JW Pharma, Actemra SC (tocilizumab SC) - Roche, Halozyme
Genentech, Inc;Genentech, Genentech
B-cell non-Hodgkin lymphoma
 
 
NCT02992522: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
22
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Beth Christian, Celgene, Genentech, Inc.
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
12/24
12/24
NCT06192888: A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting
1
39
US
Glofitamab, Obinutuzumab, Lenalidomide
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Mantle Cell Lymphoma, MCL
01/28
01/28
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
04/24
12/24
NCT06291220: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
1
80
US, RoW
Obinutuzumab, ABBV-453
AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
07/29
07/29
GO43693, NCT05364424: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Recruiting
1
40
US
Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
12/24
12/24
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Active, not recruiting
1
172
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
10/24
10/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
BP41072, NCT04077723: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
498
Europe, US, RoW
RO7227166, A CD19 Targeted 4-1BB Ligand, Obinutuzumab, Gpt, RO5072759, Gazyva, Gazyvaro, Glofitamab, CD20-TCB, RO7082859, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
03/25
03/25
 

Download Options